Please login to the form below

Not currently logged in

MorphoSys appoints Dr Markus Enzelberger as CSO

He succeeds Dr Marlies Sproll who resigns

Markus EnzelbergerGerman biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation.

Sproll will remain with the company on a part-time basis as a special advisor to chief executive officer Dr Simon Moroney, however Dr Enzelberger, who joined MorphySys in 2002, has served as its interim CSO since April this year.

Dr Enzelberger has served in various capacities at MorphoSys including senior vice president, discovery, alliances and technologies, taking responsibility for the drug discovery activities for proprietary and partnered programmes.

Dr Gerald Moller, supervisory board chairman, MorphoSys, said: “Dr Enzelberger is the perfect person to take over the CSO role at MorphoSys on a permanent basis.

“Drawing on his vast scientific expertise and experience in the management of antibody technology, research and discovery, he will continue to drive the group’s early-stage research activities with the goal of fuelling the company’s R&D pipeline with novel drug candidates in oncology and immunology.”

9th November 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...
The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...